An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A South Korean drugmaker, Samchundang Pharm, said it got feedback from the U.S. Food and Drug Administration (FDA) about how it could pursue approval for a generic version of oral semaglutide. In short: the company is talking with regulators to understand what tests and data they need to submit before they can try to bring a cheaper version of the pill form of semaglutide to market in the U.S. Semaglutide is the active ingredient in drugs you may have heard of, like Ozempic and Wegovy. It’s a man-made version of a hormone that your gut releases after you eat. That hormone tells your brain you’re full and slows the rate your stomach empties, which helps lower appetite and control blood sugar. The original semaglutide is mostly sold as a weekly injection, but there’s also an oral (pill) form that’s more convenient for some people. What the news actually reports is not a drug approval or a clinical trial result. It’s just that Samchundang Pharm received guidance from the FDA about what would be required to show their pill is equivalent to the branded oral semaglutide. The announcement doesn’t include human study results, or any claim that their product works the same; it’s an early regulatory step. FDA feedback typically covers study design, lab tests, and how to demonstrate the pill releases the drug at the right rate and in the right amount. This is about process, not proof of safety or effectiveness yet. Why this could matter is pretty practical. Branded semaglutide products have been expensive and sometimes hard to get, in part because of high demand for weight and diabetes treatments. If a generic oral version clears regulatory hurdles, it could increase competition and lower cost, and make the pill more widely available. That could be important for people who prefer a pill instead of injections, or for health systems trying to reduce medication costs. There are important caveats. FDA feedback is just guidance; it doesn’t mean the generic will be approved. A company still needs to run the required studies, submit data, and pass regulatory review. Generic manufacturing, especially for complex molecules like semaglutide, can be technically challenging. Safety and quality must be proven, and even then, patents or legal issues can delay market entry. Also, side effects known for semaglutide (like nausea, stomach upset, and rare but serious issues) would still apply; people shouldn’t switch or start any medication without a doctor’s advice. Bottom line: Samchundang got preliminary FDA advice on how to pursue a generic oral semaglutide, which is a step forward but far from a guaranteed, cheaper pill on pharmacy shelves.
Source: Chosunbiz